ALEXION PHARMACEUTICALS, INC. (ALXN) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On November 15, 2016, Alexion Pharmaceuticals, Inc. (Alexion)
received a notice from The NASDAQ Stock Market (NASDAQ) stating
that Alexion is not in compliance with NASDAQ Marketplace Rule
5250(c)(1) because Alexion has not timely filed its Quarterly
Report on Form 10-Q for the fiscal quarter ended September 30,
2016 (the Quarterly Report). The NASDAQ notice has no immediate
effect on the listing of Alexions common stock on the NASDAQ
Global Select Market.

The NASDAQ notice indicates that Alexion has until January 17,
2017 to either file the Quarterly Report or submit a plan of
compliance to NASDAQ to address any issues it believes would
support its request for an extension of time to regain compliance
with NASDAQ continued listing requirements of up to 180 calendar
days from the due date of the Quarterly Report. If Alexion is
unable to file the Quarterly Report by January 17, 2017, it
intends to submit a plan of compliance on or prior to that date.
Alexion intends to take all necessary steps to achieve compliance
with NASDAQ continued listing requirements.

Alexion issued a press release on November 16, 2016 disclosing
receipt of the notice. A copy of such press release is attached
as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.